TurtleTree Pitch Deck: All 12 Slides + Teardown

TurtleTree’s pitch deck is a highly professional example of how to leverage scientific authority and market timing in the biotech sector. Raising $30M in a Series A round in 2021, the company successfully positioned its 'Food 3.0' concept as a necessary evolution from plant-based alternatives. The deck excels at showcasing institutional validation, citing wins at the Entrepreneurship World Cup and Temasek Liveability Challenge. By highlighting a team of 21 scientists and 15 Ph.D.s, TurtleTree addresses the primary risk in deep-tech: execution capability. While the deck lacks granular unit eco…

Key takeaways

• The deck frames the industry evolution as Food 1.0 (factory farming), Food 2.0 (plant-based), and Food 3.0 (cell-based), positioning TurtleTree as the 'Revolution' on Slide 2.
• Market potential is segmented by application, showing a long-term total addressable market exceeding $125 billion across categories like infant nutrition and sports drinks on Slide 3.
• The company highlights significant historical funding, including a $6.2M pre-Series A and a $30M Series A tranche, as reported on Slide 4.
• Scientific credibility is the deck's core strength, boasting a team with 15 Ph.D.s and experience from companies like Novozymes and Merck KGaA on Slide 5.
• Geographic expansion is a key milestone, with the establishment of labs in Woodland (near UC Davis) and Boston (near MIT and Harvard) noted on Slide 4.
• The 'Buzz' slide (Slide 6) provides social proof through 250+ media mentions and features in CNN, Forbes, and The Scientist.
• Intellectual property is explicitly mentioned as a milestone, with the company having acquired IP assets and patents by 2021 on Slide 4.
• The deck omits a specific 'Ask' slide detailing the exact use of funds for the $30M round, focusing instead on past achievements and future market scale.

Frequently asked questions

What is TurtleTree's core technology?

TurtleTree develops cell-based food production technology, specifically targeting dairy ingredients like lactoferrin. As described on Slide 2, they refer to this as 'Food 3.0' or 'Food Intelligence,' which uses proprietary cellular agriculture to create functional nutrients that are identical to those found in traditional dairy but produced without factory farming.

How much did TurtleTree raise with this deck?

According to publisher-reported facts from Business Insider, TurtleTree raised $30 million in a Series A round in 2021. Slide 4 of the deck confirms this, noting they secured 'US$30M in first tranche of Series A funding,' which they claim was the largest Series A round in Asia's cell-based food sector at that time.

Who are the key members of the TurtleTree team?

The deck emphasizes a heavy scientific presence. Slide 5 highlights Dr. Amanda Fischer (Director of Strain Engineering) and Jung Yi (Director of Automation), both formerly of Novozymes. The team includes 21 scientists and 15 Ph.D.s, with additional leadership mentioned on Slide 6, including Chief Scientific Officer Dr. Aletta Schnitzler, formerly of Merck KGaA.

What markets is TurtleTree targeting?

Slide 3 outlines a broad range of high-value categories. Short-term targets include dietary supplements and protein nutrition. Mid-term targets expand into energy drinks and infant nutrition. Long-term, the company eyes massive markets like fluid milk, plant-based milk fortification, yogurt, and functional water, totaling over $125 billion in potential application value.

What milestones has the company achieved?

As of the 2022 update in the deck (Slide 4), TurtleTree had founded the company in 2019, won the Entrepreneurship World Cup, opened R&D labs in Woodland and Boston, acquired significant IP assets, and established sales channels with key industry buyers. They also completed the concept design for a Sacramento Pilot Facility.

TurtleTree pitch deck: the facts

Company

TurtleTree

Year

2021

Stage

Series A

Slides

12

Sector

Biotech

Outcome

$30M raised

TurtleTree pitch deck PDF

The full TurtleTree deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the TurtleTree pitch deck was used for

This deck is the Series A fundraising pitch used by TurtleTree in 2021 to raise US$30 million, one of the largest investment rounds in Asia’s cell-based food sector at the time.[1][5][8] TurtleTree is a Singapore- and US-based biotech company developing cell-based milk and high-value dairy ingredients such as human lactoferrin, positioned as an alternative to conventional dairy and infant formula.[9][10][12][14] The deck, shared publicly in a 2022 article, emphasizes the founders’ and team’s scientific and industry background along with the commercial potential of cell-based dairy ingredients.[5] It was used to support the first tranche of the Series A round led by VERSO Capital and other global investors.[1][2][5][8]

Business model: TurtleTree is a Singapore- and US-based biotechnology company developing cell-based technology to produce milk and milk-derived ingredients (including human breast milk and bovine dairy) without animals, aiming to license its technology and supply high-value functional ingredients such as lactoferrin to food and nutrition companies.[9][10][12][14]

Round

Series A[1][2][5][8][11]

Raised

US$30 million (Series A, first tranche)[1][5][8][11]

Lead investor

VERSO Capital[1][2][5][8]

Investors

VERSO Capital (lead investor)[1][2][5][8]

Founded

2019[14]

Founders

Fengru Lin, Max Rye[13][14]

Headquarters

Singapore, with operations in the United States.[1][10][12]

Industry

Biotechnology / FoodTech / Alternative proteins[9][10][12][14]

Year: 2021[1][2][5][6][11]

Raising: Series A funding used to scale cell-based milk and ingredient production processes to industrial level, expand the team, and build manufacturing capacity outside Singapore and in the US.[1][2][5][10]

Total funding: Multiple sources report TurtleTree’s Series A at US$30 million in 2021 and earlier seed and pre-seed rounds of roughly US$3.2 million and US$6.2 million respectively, bringing total funding to around US$39–40 million by late 2021.[2][5][11][12][14]

Use of funds as presented: Scale up cell-based milk and ingredient production to industrial levels, grow the team, and open new manufacturing facilities outside Singapore and in the United States.[1][2][5][10]

What happened after the TurtleTree deck

Following its US$30 million Series A in 2021, TurtleTree moved to scale its cell-based milk and ingredient technologies through industrial partnerships and continued to position itself as a leading player in cell-based dairy and human milk ingredients.[1][2][5][7][10][11][12]

• Completion of a US$30 million first tranche Series A round in late 2021, described as one of Asia’s largest cell-based f
• Progression from R&D toward industrial-scale production, including a partnership with US-based biomanufacturing company
• Expansion of focus from broad cell-based milk toward specific high-value functional ingredients like human lactoferrin,

What the TurtleTree deck got right

• Clear articulation of a very large, high-value target market. The company operates in a very large and well-defined market: global dairy (circa US$700 billion) and infant nutrition, with a unique focus on cell-based milk and human breast milk that can match conventional composition, taste, and functionality.[9][12][14][15] This substantial market framing is a strong asset in the deck.
• Differentiated, proprietary technology with first-mover positioning. TurtleTree’s proprietary cell-based technology and positioning as one of the first or leading companies to produce the full composition of milk from mammalian cells give the deck a strong differentiation narrative.[9][12][14][15] This pioneering status likely resonated with investors seeking frontier food-tech.
• Strong scientific and founding-team credibility. The founding team and scientific staff bring credible expertise in biotechnology and related fields, and the deck reportedly emphasizes this scientific pedigree.[5][9][12][14][15] For an early-stage biotech, this is a key strength in de-risking technical execution.
• Use of funds linked to tangible scale-up and expansion plans. External coverage indicates that the Series A pitch tied the raise to concrete operational uses of funds—industrial scale-up, team growth, and new facilities in the US and beyond—rather than purely R&D.[1][2][5][10] This grounding in operational milestones strengthens the fundraising narrative.
• Platform framed around multiple high-value ingredient applications. By focusing not only on consumer-facing cell-based milk but also on specific high-value ingredients such as lactoferrin and human milk components, TurtleTree’s platform story offers multiple commercial entry points and B2B applications.[10][12][14][15] This multi-application framing is a strategic strength in the deck.
• Validation through a large, high-profile Series A raise. The Series A round size (US$30 million) and characterization as one of the largest cell-based food investments in Asia provide social proof that the deck successfully convinced sophisticated investors, reinforcing its perceived strength for future readers.[1][5][8][11]

What could have been stronger

• Limited clarity on near-term commercial milestones. External descriptions emphasize TurtleTree’s long-term focus on full cell-based milk and human breast milk, which are complex, highly regulated markets with long timelines to consumer products.[9][12][14] A Series A deck that leans heavily on scientific pedigree and broad market potential, without clear near-term, de-risked product milestones (e.g., specific ingredient launches, regulatory strategy, or B2B contracts), may leave investors uncertain about commercialization timelines and early revenue paths.
• Insufficient visible economics and scale-up detail. The public article about the deck highlights scientific credentials and market size, but does not describe detailed unit economics, manufacturing costs, or scale-up assumptions.[5] Given the capital- and process-intensive nature of cell-based biomanufacturing, absence of visible cost curves, capex plans, or margin projections in the deck would be a material gap for investors assessing the feasibility of industrial-scale production.
• Regulatory and safety strategy not foregrounded. Cell-based milk and human breast milk touch regulated categories such as novel foods and infant nutrition, yet public materials around the Series A emphasize technology and market disruption more than regulatory pathways.[9][10][12] If the deck similarly downplays regulatory timelines, jurisdiction-by-jurisdiction strategy, and safety validation plans, investors may view that as a structural weakness in the pitch.
• Limited disclosed commercial traction at Series A stage. The deck’s framing in press coverage focuses on TurtleTree’s pioneering status and large market opportunity rather than concrete commercial traction metrics such as signed partnerships, pilot volumes, or revenue.[5][10] For a Series A, limited disclosure of external validation (e.g., paying customers, long-term supply agreements) would be a gap, even if typical for deep-tech biotech.

How an investor would read this deck

What draws attention

• Evidence of robust, defensible proprietary technology for producing cell-based milk and high-value ingredients, including proof that the process can be scaled in bioreactors while maintaining composition and functionality similar to conventional milk.[9][10][12][15]
• Clarity on the company’s path from R&D to industrial-scale manufacturing, including timelines, capex requirements, and partnerships with specialist biomanufacturing firms such as Solar Biotech.[10]
• The size and growth potential of markets for high-value dairy-derived ingredients (like lactoferrin and human milk components), and how TurtleTree can compete with incumbent dairy and fermentation-based producers using a potentially lower-carbon, animal-free process.[9][10][12][14][15]
• Founders’ and team’s scientific and operational credentials, as the deck reportedly focuses heavily on scientific pedigree, which is central to de-risking the technology and regulatory journey.[5][9][12]
• Evidence that investors such as VERSO Capital and earlier backers bring not only capital but also strategic capabilities in scaling food-tech and biotech ventures, helping to bridge TurtleTree from pilot stages to commercial deployment.[1][2][5][11][14]

Risks that stand out

• Technical scale-up risk: moving from lab-scale cell-based milk and ingredient production to industrial bioreactors involves significant challenges in cell behavior, consistency, contamination control, and process economics.[9][10][12][15]
• Regulatory and market-acceptance risk: cell-based human breast milk and dairy ingredients face regulatory scrutiny and may encounter consumer hesitancy in sensitive categories such as infant nutrition.[9][12]
• Capital intensity and timeline risk: the path to full commercialization of cell-based milk can require substantial capital over many years, exposing investors to dilution and execution risk if near-term, revenue-generating ingredient applications are not strongly developed.[9][10][12][14]
• Competitive risk: other alternative protein and dairy-tech companies using precision fermentation or plant-based approaches may reach market sooner with lower regulatory burden, potentially capturing key B2B relationships TurtleTree targets.[9][10][14][15]

Questions this deck invites

• What specific products or ingredients (e.g., lactoferrin, other bioactive components) were prioritized for first commercial launch at the time of the Series A, and what validated data (safety, functionality, cost) supported those choices?[9
• How does TurtleTree’s cell-based milk and ingredient production process compare in cost, scalability, and environmental impact to precision fermentation and conventional dairy in the target markets, based on quantitative benchmarks?[9][10][
• What regulatory strategy did TurtleTree outline in the Series A deck for novel food approvals and infant nutrition products in jurisdictions such as the US, EU, and Singapore, and what independent advisors or agencies were engaged?[9][10][1
• Which commercial or R&D partnerships (for example, with biomanufacturing firms like Solar Biotech, or with food and infant nutrition companies) were already signed or in advanced negotiation at the time of the raise, and what revenue or vol
• How was the US$30 million Series A budget allocated across R&D, scale-up, regulatory, and commercial activities, and what specific milestones (e.g., pilot volumes, first commercial shipments) were tied to this tranche of funding?[1][2][5][1

What founders can take from the TurtleTree deck

• Deep-tech food and biotech startups can successfully raise large Series A rounds by clearly communicating a compelling scientific edge and the scale of the market opportunity, even when consumer products are years away, as seen in TurtleTree’s US$30 million Series A.[1][2][5][11]
• Positioning around high-value, functional ingredients (such as lactoferrin and human milk components) can make a cell-based milk platform more investable at Series A by offering nearer-term B2B applications and clearer commercial pathways.[10][12]
• Highlighting strategic manufacturing partnerships and a concrete scale-up roadmap (for example, collaborations with biomanufacturing specialists) helps investors understand how a lab technology can become an industrial process.[10]
• Combining strong founding-team credentials in science and entrepreneurship with recognition from global awards and media coverage increases credibility and may reduce perceived technology risk in early-stage biotech fundraising.[5][9][13][14]
• Transparently articulating total funding to date and how previous rounds (seed and pre-A) have de-risked the technology sets context for why a larger Series A tranche is appropriate, as TurtleTree and its coverage explicitly discuss cumulative raises.[2][5][11][12][14]
• Leveraging public pitch deck exposure after the round (such as sharing the Series A deck via media) can serve as a branding and education tool for the company’s technology and mission, beyond the fundraising itself.[5]

TurtleTree pitch deck: common questions

What does TurtleTree do?

TurtleTree is a biotechnology and food-tech startup based in Singapore and the United States that develops cell-based technology to produce milk and milk-derived functional ingredients, including human breast milk and bovine milk, without using animals.[9][10][12][14]

How much did TurtleTree raise in its Series A round and when?

TurtleTree’s Series A round was announced in late 2021 as a US$30 million raise, described as the first tranche of its Series A funding and one of the largest investment rounds in Asia’s cell-based food sector.[1][5][8][11] The company indicated that the capital would be used to scale its processes to industrial levels, grow its team, and build manufacturing capacity outside Singapore and in the US.[5]

Who led TurtleTree’s Series A and who were the investors?

The Series A round was led by VERSO Capital, with participation from investors worldwide; some earlier investors such as Green Monday Ventures, KBW Ventures, CPT Capital, Artesian, and others had backed the company in prior seed and pre-A rounds.[1][2][5][11][14] Public sources name VERSO Capital as the lead investor for the US$30 million Series A.[1][2][5][8]

What was TurtleTree raising its Series A funding for?

According to press coverage, TurtleTree planned to use its US$30 million Series A funding to move from R&D to commercial scale by getting its cell-based milk and ingredient production processes ready for industrial scale, expanding its team, and opening new manufacturing facilities outside of Singapore and in the United States.[1][2][5][10]

What products or applications was TurtleTree focusing on, and how has that evolved?

At the time of the 2021 Series A deck, TurtleTree’s focus was on cell-based milk and human breast milk as alternatives to conventional dairy and infant formula.[9][12][14] In subsequent years, the company’s public communications increasingly highlighted specific high-value ingredients such as human lactoferrin and partnerships to scale up biomanufacturing on a commercial scale.[10]

Sources

Funding and outcome facts on this page were researched on 2026-08-30 from the pages below.

• TurtleTree Raises US$30 Million in First Tranche of Series A Funding
• TurtleTree Raises $30 Million In Series A To Expedite Full ... - Forbes
• TurtleTree: Funding, Team & Investors | Startup Intros
• TurtleTree - 2026 Funding Rounds & List of Investors
• The Pitch Deck Food-Tech Startup TurtleTree Used to Raise $30 ...
• Total Raised
• Lactoferrin startup TurtleTree raising $15M pre-Series B
• Turtle Tree $30 Million series a 2021-11-01 - Fundings - Fundz

Related fundraising guides (24)

• Hedra Pitch Deck Teardown: A $32M Series A Built on Capital-Efficient AI Research
• Kinnu Pitch Deck Teardown: A Masterclass in Social Proof and Product-Led Growth
• Nest Health Pitch Deck Teardown: A $15M Seed Strategy for Value-Based Family Care
• Orchid Pitch Deck Teardown: A Masterclass in High-Stakes Clinical Validation
• Cove.Tool Pitch Deck Teardown: A Masterclass in Visualizing Efficiency Gains
• Connected Analytics Pitch Deck Teardown: Solving the Cash-Loyalty Gap in Africa
• Limetree Pitch Deck Teardown: A Case Study in Early-Stage Family Media Preservation
• Moonlight Pitch Deck Teardown: A Community-First Approach to Remote Engineering
• Staffjoy Pitch Deck Teardown: A Masterclass in Algorithmic Workforce Automation
• Swipes Pitch Deck Teardown: A Minimalist Approach to Productivity Fundraising
• Thematic Pitch Deck Teardown: Leveraging Creator Networks for Scalable Music Promotion
• Yalo Pitch Deck Teardown: Dominating Enterprise Conversational AI via WhatsApp
• Curio.io Pitch Deck Teardown: Selling High-Engagement Audio Journalism
• Odeko Pitch Deck Teardown: A Masterclass in Obfuscating Real Traction Numbers
• RegioHelden Pitch Deck Teardown: A Masterclass in Local Marketing Unit Economics
• Trash Warrior Pitch Deck Teardown: Disrupting the $56B Commercial Waste Collection Market
• Yelp Pitch Deck Teardown: A Post-IPO Growth Story Focused on Local Ad Dominance
• Yuzu Health Pitch Deck Teardown: A Masterclass in Market Education and Infrastructure Replacement
• Vespa.ai Pitch Deck Teardown: A Corporate Spin-Out Strategy for High-Scale Vector Search
• Heali Pitch Deck Teardown: Leveraging Clinical Validation to Secure a $3M Seed Round
• Viso Pitch Deck Teardown: A 42-Slide Masterclass in Computer Vision Infrastructure
• Sunnyside Pitch Deck Teardown: A Masterclass in Market Expansion via Habit Modification
• micro1 Pitch Deck Teardown: Leveraging Growth Momentum and AI Vetting for Global Engineering
• Layla Pitch Deck Teardown: A $3M Seed Round Built on AI-Powered Travel Discovery

This deck's categories (1)

• Series A & Series B Pitch Deck Examples

Decks from the same year (1)

• 2021 pitch deck examples

Decks with a similar raise (1)

• Pitch decks that raised $10M to $50M

Browse companies alphabetically (1)

• Pitch decks from companies starting with T

Decks in the same category (12)

• MySQL 2003 Series B Pitch Deck Breakdown
• Oscar Health Pitch Deck Breakdown
• LinkedIn 2004 Pitch Deck Breakdown: How Networks Became the Next Big Thing
• DoggyHut Pitch Deck Breakdown: The Perfect Series A Deck For A Company That Does Not Exist
• Monzo Pitch Deck Breakdown: Building the Bank of the Future
• Pendo Series B Pitch Deck Breakdown
• Taster Pitch Deck Breakdown: Scaling Digital Restaurant Brands via a Licensing Model
• Zio Studios Pitch Deck Breakdown: A Transmedia Pivot from Services to IP
• Hadean Pitch Deck Breakdown: Proving Technical Scale Through Enterprise Case Studies
• Now Pitch Deck Breakdown: A $29M Series A Built on Municipal Bond Securitization
• Hangry Pitch Deck Breakdown: Scaling Multi-Brand Virtual Restaurants in Indonesia
• Seedtag Pitch Deck Breakdown: Leveraging the Post-Cookie Era with Contextual AI

More pitch deck teardowns (16)

• Tucana Real Estate Pitch Deck Teardown: A €8.6M Equity Ask for Munich Housing
• Tuinleren Pitch Deck Teardown: A Hyper-Local Gardening Play Seeking €372.5k
• Tulipshare Pitch Deck Breakdown: Weaponizing Retail Investing for Shareholder Activism
• Tulu Pitch Deck Teardown: Selling the 'Usage Economy' Through Smart Amenity Kiosks
• Tunibibi Pitch Deck Teardown: Solving Cross-Border E-commerce Logistics for Bangladesh
• Turbo Boom Pitch Deck Breakdown: A Solo Developer's Micro-Budget Indie Game Strategy
• Turned International Agriculture LLC Pitch Deck Teardown: A $20M Plan for Turkish Hemp
• Turned International Agriculture Pitch Deck Teardown: A $20M Request for a Zero-Staff Startup
• TurtleWise Pitch Deck Teardown: A $1M Ask for a Verified Advice Marketplace
• Tushky Pitch Deck Breakdown: A 2011 Snapshot of the Indian Sharing Economy
• Tutkimusparvi Pitch Deck Teardown: A Case Study in Open Research Swarms
• Tutoring Pitch Deck Teardown: Scaling On-Demand Language Learning in South Korea
• TVI Pacific Inc. Pitch Deck Teardown: A Resource-Heavy Mining and Agribusiness Play
• TVI Pacific Pitch Deck Teardown: A Case Study in Resource Diversification and JV Structures
• TVI Pacific Pitch Deck Teardown: A Resource Developer's Guide to Bootstrap Mining Growth
• TVision Pitch Deck Breakdown: A Masterclass in Market Shift and Data Calibration

Recently published pitch deck teardowns (12)

• 8Merch.com Pitch Deck Teardown: A Zero-Commission Play for the Independent Music Market
• 7 Bridges Pitch Deck Teardown: A Masterclass in Visualizing Logistics Complexity
• 40Seas Pitch Deck Teardown: A Masterclass in High-Signal Fintech Credibility
• 98point6 Technologies Pitch Deck Teardown: A $30.7M Pivot from Care Delivery to SaaS Licensing
• Anvil Pitch Deck Teardown: A Masterclass in High-Level Narrative and Product Abstraction
• Cellarity Pitch Deck Teardown: A $121M Series C Masterclass in Platform-First Biotech
• Circles Pitch Deck Teardown: A $16.5M Series A Bet on Scalable Peer Support
• Cleary Pitch Deck Teardown: A Land-and-Expand Strategy for Remote Employee Experience
• Claira Pitch Deck Teardown: Solving the Legal Logic Gap in Financial Contracts
• Chattermill Pitch Deck Teardown: A Masterclass in Enterprise Social Proof and Expansion Strategy
• Coram AI Pitch Deck Teardown: A $13.8M Series A Built on Large-Vision Language Models
• Constructor Pitch Deck Teardown: A Masterclass in Retention-Led Series B Storytelling

Fundraising library · Pitch deck examples · Investor directory · Founder database